References

vtio

Вестник трансплантологии и искусственных органов

Russian Journal of Transplantology and Artificial Organs

1995-1191

Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation

10.15825/1995-1191-2012-2-98-109

vtio-169

Research Article

Обзор литературы

Literature Reviews

СОВРЕМЕННАЯ ТАКТИКА ИММУНОСУПРЕССИВНОЙ ТЕРАПИИ КАК СПОСОБ ФОРМИРОВАНИЯ ТОЛЕРОГЕННОЙ СТРАТЕГИИ ОРГАНИЗМА (НА ПРИМЕРЕ ТРАНСПЛАНТАЦИИ ПЕЧЕНИ)

THE MODERN IMMUNOSUPPRESSIVE TACTICS AS A WAY FOR INDUCING OF TOLEROGENIC STRATEGY AFTER LIVER TRANSPLANTATION (ANALYSIS OF THE PROBLEM STATUS)

Артамонов

С. Д.

Artamonov

S. D.

Великий

Д. А.

Velikiy

D. A.

Онищенко

Н. А.

Onischenko

N. A.

Крашенинников

М. Е.

Krasheninnikov

M. E.

Иванов

И. М.

Ivanov

I. M.

Башкина

Л. В.

Bashkina

L. V.

Никольская

А. О.

Nikolskaya

A. O.

ФГБУ «ФНЦ трансплантологии и искусственных органов им. академика В.И. Шумакова» Минздравсоцразвития России, г. МоскваAcademician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow

2012

28052014

142

ВЕСТНИК ТРАНСПЛАНТОЛОГИИ И ИСКУССТВЕННЫХ ОРГАНОВ том XIV No 2–2012

98109

2012

Артамонов С.Д., Великий Д.А., Онищенко Н.А., Крашенинников М.Е., Иванов И.М., Башкина Л.В., Никольская А.О.

Artamonov S.D., Velikiy D.A., Onischenko N.A., Krasheninnikov M.E., Ivanov I.M., Bashkina L.V., Nikolskaya A.O.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.transpl.ru/vtio/article/view/169

В статье обсуждается необходимость разработки индивидуальной тактики медикаментозной иммуно- супрессии при трансплантации органов (печени). Авторы полагают, что препараты, их дозы и схемы применения не должны препятствовать регуляции иммунитета. Их назначение – тормозить образование эффекторных клеток и клеток памяти, а также способствовать индукции естественных механизмов толе- рантности и репаративной регенерации, тормозящих процессы фиброзирования органов (печени). Для оптимизации медикаментозной иммуносупрессии при трансплантации печени в клинике авторы предлагают выявлять толерогенные группы реципиентов, а также разрабатывать и применять инфор- мативные диагностические и прогностические методы для оценки уровня и степени индивидуальной толерогенной устойчивости реципиентов.

In this article the necessity of working out of individual therapeutical immunosuppressive tactics was consi- dered. The authors believe that doses and schemes of used drugs must not prevent the immunity regulation. Immunosuppressive drugs must induce native mechanisms of immune tolerance and reparative regeneration for preventing of fibrotic processes in grafts (liver). For optimal effect of drug immunosuppression after clinical liver transplantation it was suggested to reveal tole- rogenic recipient’s groups and also to work out and use informative diagnostic and prognostic methods for value of individual level and power tolerance stability of recipients.

иммуносупрессивная терапиятолерантностьфиброзирование при трансплантации печени

immunosuppressive therapytolerancefibrosis at liver transplantation.

References1

Артамонов С.Д., Онищенко Н.А., Башкина Л.В. и др. Роль систем врожденного и адаптивного иммунитета в развитии деструктивного иммунного ответа организ- ма на аллотрансплантат // Вестник трансплантологии и искусственных органов. 2010. Т. 12, No 3. С. 112–120.

Артамонов С.Д., Онищенко Н.А., Башкина Л.В. и др. Система аутотолерантности и ее функционирование при трансплантации аллогенных органов // Вестник трансплантологии и искусственных органов. 2010. Т. 12, No 3. С. 121–128.

Бабаева А.Г., Геворкян Н.М., Зотиков Е.А. Роль лим- фоцитов в оперативном изменении программы раз- вития тканей. М.: РАМН, 2009. 107 с.

Готье С.В. Иммуносупрессия при трансплантации солидных органов. М.: Триада, 2011. 470 с.

Abu-Elmagd K.M., Costa G., Bond G.J. et al. Evolution of the immunosuppressive strategies for theintestinal and multivisceral recipients with specialreference to allograft immunity and achievement of partial tolerance // Euro- pean Society for Organ Transplantation. 2009. Vol. 22. P. 96–109.

Adeyi O., Fischer S.E., Guindi M. Liver allograft patho- logy: approach to interpretation of needle biopsies with clinicopathologicalcorrelation // J. Clin. Pathol. 2010.

Vol. 63. P. 47–74.

Ashton-Chess J., Giral M., Soulillou J-P., Brouard S.

Can immune monitoring help to minimize immunosup- pression in kidney transplantation? // Transpl. Int. 2009. Vol. 22. P. 110–119.

Azzi J., Sayegh M.H. Clinical transplantation tolerance: a myth no more, but // Am. J. Kidney Dis. 2009. Vol. 54. P. 1005–1011.

Bakr M.A. Induction therapy // Experimental and Clini- cal Transplantation. 2005. Vol. 3 (1). P. 320–328.

Bishop G.A., Ierino F.L., Sharland A.F., Hall B.M. et al. Approaching the promise of operational tolerance in cli- nical transplantation // Transplantation. 2011. Vol. 91, No 10. P. 1065–1074.

Bucuvalas J. Long-term outcomes in pediatric liver trans- plantation // Liver Transplantation. 2009. Vol. 15. P. 6–11.

Calne R., Friend P., Moffatt S. et al. Prope tolerance, pe- rioperative campath 1H, and low-dose cyclosporin mo- notherapy in renal allograft recipients // Lancet. 1998.

Vol. 351. P. 1701–1702.

Carey E., Carey W.D. Noninvasive tests for liver disease,

fibrosis, and cirrhosis: Is liver biopsy obsolete? // Cleveland

Clinic Journal of Medicine. 2010. Vol. 77 (8). P. 519–527.

Charlton M.R., Wall W.J., Ojo A.O. et al. International Liver Transplantation Society Expert Panel. Report of the first international liver transplantation society ex- pert panel consensus conference on renal insufficiency in liver transplantation // Liver Transplantation. 2009.

Vol. 15. P. 1–34.

De Serres S.A., Sayegh M.H., Najafian N. Immunosup-

pressive drugs and Tregs: a critical evaluation! // Clin. J.

Am. Soc. Nephrol. 2009. Vol. 4. P. 1661–1669.

Demetris A.J., Lunz J.G., Randhawa P. et al. Monitoring of human liver and kidney allograft tolerance:a tissue/ histopathology perspective 2008 European Society for

Organ // Transplantation. 2009. Vol. 22. P. 120–141.

Dousset B., Hubscher S.G., Padbury R.T. et al. Acute liver allograft rejection – is treatment always necessa-

ry? // Transplantation. 1993. Vol. 55. P. 529–534.

Feng S. Long-term management of immunosuppression after pediatric liver transplantation: is minimization or withdrawal desirableand/or possible? // Curr. Opin. Or-

gan Transplant. 2008. Vol. 13 (5). P. 506–512.

Ford M.L., Larsen C.P. Translating costimulation blocka- de to the clinic: lessons learned from three pathways //

Immunol Rev. 2009. Vol. 229 (1). P. 294–306.

Gangappa S., Kokko K.E., Carlson L.M. et al. Immune responsiveness and protective immunity after transplan-

tation // Transpl. Int. 2008. Vol. 21. P. 293–303.

Girlanda R., Kirk A.D. Frontiers in Nephrology: Immu- ne Tolerance to Allografts in Humans // J. Am. Soc. Ne-

phrol. 2007. Vol. 18. P. 2242–2251.

Holt A.P., Salmon M., Buckley C.D., Adams D.H. Immu-

ne interactions in hepatic fibrosis or «Leucocyte-stro- malinteractions in hepatic fibrosis» // Clin. Liver Dis. 2008. Vol. 12 (4). P. 861–885.

Kawai T., Cosimi A.B., Spitzer T.R. et al. HLA-Mismat- ched renal transplantation without maintenance immu- nosuppression // NEJM. 2008. Vol. l4 (358). P. 353–361.

Kirk A.D., Hale D.A., Mannon R.B. et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtu- zumab (Campath-1H) // Transplantation. 2003. Vol. 76 (1). P. 120–129.

Krams S.M., Martinez O.M. Epstein Barr virus, rapa- mycin, and host immune responses // Curr. Opin Organ Transplant. 2008. Vol. 13 (6). P. 563–568.

Letourneau S., Krieg C., Pantaleo G., Boyman O. IL- 2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets // J. Allergy. Clin. Immunol. 2009. Vol. 123. P. 758–762.

Li X.C., Turka L.A. An update on regulatory T cells in transplant tolerance and rejection // Nat. Rev. Nephrol. 2010. Vol. 6. P. 577–583.

Libby P., Pober J.S. Chronic rejection. Immunity. 2001. Vol. 14. P. 387–397.

Magee J.C. Graft fibrosis in stable pediatric liver trans- plant recipients: What does it mean? // Hepatology. 2009. Vol. 49 (3). P. 726–728.

Martinez O.M., Rosen H.R. Basic concepts in transplant immunology // Liver Transplantation. 2005. Vol. 11 (4). P. 370–381.

Mazariegos G.V. Immunosuppression withdrawal after liver transplantation: what are the next steps? // Trans- plantation. 2011. Vol. 91. P. 697–699.

Morelli A.E., Larregina A.T. Apoptotic cell-based thera- pies against transplant rejection: role of recipient’s dend- ritic cells // Apoptosis. 2010. Vol. 15. P. 1083–1097.

Movahedi Z., Holt C.D., Saab S. Liver transplant: a pri- mer // Experimental and Clinical Transplantation. 2010. Vol. 8 (2). P. 20–25.

Natarajan S., Thomson A.W. Tolerogenic dendritic cells and myeloid-derived suppressor cells: potential for re- gulation and therapy of liver auto- and alloimmunity // Immunobiology. 2010. Vol. 215 (9–10). P. 698–703.

Nath D.S., Basha H.I., Mohanakumar T. Anti-human leukocyte antigen antibody induced autoimmunity:role in chronic rejection // Curr Opin Organ Transplant. 2010. Vol. 15 (1). P. 16–20.

Pearl J.P., Parris J., Hale D.A. et al. Immunocompe- tent T-cells with a memory-like phenotype are the do- minant cell type following antibody-mediated T-cell depletion // Am. J. of Transplantation. 2005. Vol. 5. P. 465–474.

Pham P-T., Lipshutz G.S., Kawahji J., Singer J.S. The evolving role of alemtuzumab (Campath-1H) in renal transplantation // Drug Design, Development and Thera- py. 2009. Vol. 3. P. 41–49.

Reding R., Gras J., Truong D.Q. et al. The Immunolo- gical monitoring of alloreactive responses in liver trans- plant recipients:a review // Liver Transplantation. 2006. Vol. 12. P. 373–383.

Riley J.L., June C.H., Blazar B.R. Human T regulatory cells as therapeutic agents: take a billionor so of these and call me in the morning // Immunity. 2009. Vol. 30 (5). P. 656–665.

Rostaing L., Kamar N. mTOR inhibitor/proliferation sig- nal inhibitors: entering or leaving the field? // J. Nephrol. 2010. Vol. 23 (2). P. 133–142.

Sampaio E.L., Freitas T.V., Galante N.Z. et al. Alem- tuzumab induction in kidney transplant recipients // J. Bras. Nefrol. 2010. Vol. 32. P. 89–97.

Sanchez–Fueyo A., Strom T.B. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs // Gastroenterology. 2011. Vol. 140. P. 51–64.

Schwartz M., Cohen I.R. Autoimmunity can benefit self-maintenance // Immunol Today. 2000. Vol. 21 (6). P. 265–268.

Seetharam A., Tiriveedhi V., Mohanakumar T. Alloim- munity and autoimmunity in chronic rejection // Curr. Opin Organ Transplant. 2010. Vol. 15 (4). P. 531–536.

Sewgobind V.D., van der Laan L.J., Kho M.M. et al. The calcineurin inhibitor tacrolimus allows the induc- tion of functional CD4CD25 regulatory T-cells by rabbit anti-thymocyte globulins // Clin. Exp. Immunol. 2010. Vol. 161 (2). P. 364–377.

Spada M., Riva S., Maggiore G. et al. Pediatric liver transplantation // World J. Gastroenterol. 2009. Vol. 14– 15 (6). P. 648–674.

Starzl T.E., Lakkis F.G. The Unfinished legacy of liver transplantation: emphasis on immunology // Hepatology. 2006. Vol. 43. P. 151–163.

Starzl T.E. Chimerism and tolerance in transplantation // PNAS. 2004. Vol. 101 (2). P. 14607–14614.

Strick-Marchand H., Masse G.X., Weiss M.C., Di San- to J.P. Lymphocytes support oval cell-dependent liver regeneration // The Journal of Immunology. 2008. Vol. 181. P. 2764–2771.

Tao R., Hancock W.W. Regulating regulatory T-cells to achieve transplant tolerance // Hepatobiliary Pancreat Dis Int. 2007. Vol. 6. P. 348–357.

Waid T.H., Thompson J.S., Siemionow M.S., Brown A. T10B9 monoclonal antibody: A short-acting nonstimu- lating monoclonal antibody that spares γδ T-cells and treats and prevents cellular rejection // Drug Design, De- velopment and Therapy. 2009. Vol. 3. P. 205–212.

Wiesner R.H., Demetris A.J., Belle S.H. et al. Acu- te hepatic allograft rejection: incidence, risk factors, and impact on outcome // Hepatology. 1998. Vol. 28. P. 638–645.

The authors declare that there are no conflicts of interest present.